<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427700</url>
  </required_header>
  <id_info>
    <org_study_id>RACLO</org_study_id>
    <nct_id>NCT00427700</nct_id>
  </id_info>
  <brief_title>Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome</brief_title>
  <official_title>Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Polycystic Ovarian Syndrome (PCOS) is a common disorder related to ovulation problems.
      Clomiphene citrate (CC) is the drug of first choice for this condition. Nevertheless, CC has
      a detrimental effect over uterine receptivity.

      Raloxifene is a Selective Estrogen Receptor Modulator, that does not have a detrimental
      effect over the endometrium, and also increase the serum levels of FSH, thus, inducting
      ovulation.

      The objective of this study is to compare the ovulation rate in PCOS patients between
      clomiphene citrate and raloxifene in a double blind randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -Introduction The Polycystic Ovarian Syndrome (PCOS) is a frequent endocrine among women in
      reproductive ages, with a prevalence of 10%. In 2003, a consensus among the European and
      American Society of Human Reproduction (ESRHE and ASRM) defined that PCOS is a ovarian
      disfunction which present at least 2 out of 3 criteria: oligomenorrhea or anovulation;
      clinical or laboratorial signs of hyperandrogenism and polycystic ovaries on ultrasound;
      other causes, such as congenital adrenal hyperplasia, androgen secretory tumors, Cushing
      syndrome and hyperprolactinemia must be rule out.

      Patients with PCOS who desire to became pregnant need, in their majority, induction of
      ovulation. Traditionally, clomiphene citrate, an estrogen receptor agonist, is the most used
      drug for this type of anovulation. The mechanism of action of clomiphene is related to a
      negative feedback to the endogenous estrogen, resulting in a higher amplitude of
      gonadotrophin surges, i.e., luteinizing hormone(LH) and follicle stimulating hormone(FSH).
      Nevertheless, recent studies have been shown that clomiphene citrate has a deleterious effect
      in the endometrium. The markers of uterine receptivity, among them, the integrin beta3
      subunit, has its expression diminished, which implicate in a reduced fecundation rate.

      The raloxifene is a selective estrogen receptor modulator. It has an agonist and antagonist
      activity over different organs. The daily therapy with raloxifene increase bone density,
      reduce cholesterol serum concentrations (LDL) and do not stimulate the endometrium in
      post-menopausal women (Delmas PD et al., 1997). Recent studies have shown that this drug is
      safe in healthy pre-menopausal women (Baker VL et al., 1998). A daily dosi of 100mg per 28
      days, beginning on the 3rd day of the cycle, has shown that FSH and LH levels were not
      affected when compared to controls during the menstrual cycle. However, women who had
      received 100mg of raloxifene had a 31% increase in their FSH serum levels during the
      follicular phase, when compared to controls. An increase to 200mg did not increase FSH levels
      (Baker VL et al, 1998). Furthermore, it has been shown that raloxifene significantly increase
      the in vitro expression of αvβ3 integrin, suggesting a beneficial effect over the endometrium
      in relation to clomiphene (Lessey BA, personal communication, 2006).

      -Objective To compare the ovulation rate between raloxifene and clomiphene among women with
      polycystic ovarian syndrome.

      To identify the endometrial alterations compatible with ovulations, i.e., secretory
      endometrium, through endometrial biopsy between the women who used raloxifene or clomiphene.

      -Patients and Methods

      Patients with the diagnosis of polycystic ovarian syndrome (because of infertility or
      hirsutism) who had a consultation at outpatient clinic of Hospital de Clínicas de Porto
      Alegre will be invited to participate in the study, after signing the informed consent. A
      standard interview will be performed. In the first consultation, the laboratorial exams will
      reviewed: total testosterone, 17 OH-progesterone, fasting glucose, TSH, prolactin. After the
      interview, the patient will be randomized for one of the treatments:

      100mg of clomiphene or 100mg of raloxifene from day 3 of the menstrual cycle, for 5 days.
      Menstruation will be induced with 10mg of oral medroxyprogesterone per 10 days. On day 10,
      urinary LH will be collected daily along with endovaginal ultrasound for assessing follicular
      development. On post-ovulatory day 8~10, progesterone levels will be measured from blood. An
      endometrial biopsy on day 8~10 post-ovulation will be performed in those patients who do not
      wish to became pregnant. The endometrial biopsy will divided into 2 parts and kept in liquid
      nitrogen and formol for immunohistochemistry and histological analysis respectively.

      Sample size and statistical analysis

      Ethical aspects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Ovulation Detected by Ultrasound</measure>
    <time_frame>cycle day 14-20</time_frame>
    <description>Ovulation detected by ultrasound was defined as the percentage of a participants with ovulation detected by ultrasound, defined as the dominant follicle and its subsequent collapse. If a dominant follicle was not observed by day 21 after menses, the ovulation induction was considered to be a failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Progesterone</measure>
    <time_frame>8-10 days after ovulation</time_frame>
    <description>The level of serum progesterone that indicated ovulation was considered to be 3 ng/mL or greater, on days 8 to 10 after ovulation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Clomiphene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raloxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of 100mg of raloxifene during days 5-9 of the menstrual cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate</intervention_name>
    <description>100mg PO on days 5-9 of the menstrual cycle</description>
    <arm_group_label>Clomiphene</arm_group_label>
    <other_name>Clomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raloxifene</intervention_name>
    <description>100mg PO on days 5-9 of the menstrual cycle</description>
    <arm_group_label>Raloxifene</arm_group_label>
    <other_name>Evista</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with polycystic ovarian syndrome will be invited to participate in the
             study. The PCOS criteria are according to modified Rotterdam criteria (7); i.e.,
             oligoovulation defined as &lt; 6 menstrual periods per year, signs of clinical
             hyperandrogenism (Ferriman and Gallwey &gt;8) or laboratorial (total Testosterone &gt;=0.81
             ng/dL) or polycystic ovary &gt; 10cm3.

        Furthermore, all patients with infertility diagnosis based solely on ovulation factor will
        included in the protocol

          -  Age &gt;18 years old and &lt;= 38 years old.

          -  No endometriosis on laparoscopy

        Exclusion Criteria:

          -  Not willing to participate in the study

          -  use of IUD or contraceptive pill within 2 months before the study.

          -  Hyperprolactinemia (&gt;20ng/mL)

          -  Abnormal serum levels of TSH(normal range:0.4-40 mUI/mL).

          -  High 17-OH progesterone (&gt;=4.9ng/mL)

          -  Endometriosis

          -  Known allergy to clomiphene or raloxifene
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo F Savaris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Corleta, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce A Lessey, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Greenville Hospital System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997 Dec 4;337(23):1641-7.</citation>
    <PMID>9385122</PMID>
  </reference>
  <reference>
    <citation>Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 1998 Jan;83(1):6-13.</citation>
    <PMID>9435408</PMID>
  </reference>
  <reference>
    <citation>Grimes DA. The &quot;CONSORT&quot; guidelines for randomized controlled trials in Obstetrics &amp; Gynecology. Obstet Gynecol. 2002 Oct;100(4):631-2.</citation>
    <PMID>12383524</PMID>
  </reference>
  <reference>
    <citation>Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001 Apr 18;285(15):1987-91. Review.</citation>
    <PMID>11308435</PMID>
  </reference>
  <reference>
    <citation>Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006 Mar;91(3):781-5. Epub 2006 Jan 17.</citation>
    <PMID>16418211</PMID>
  </reference>
  <reference>
    <citation>Lessey BA, Ilesanmi AO, Lessey MA, Riben M, Harris JE, Chwalisz K. Luminal and glandular endometrial epithelium express integrins differentially throughout the menstrual cycle: implications for implantation, contraception, and infertility. Am J Reprod Immunol. 1996 Mar;35(3):195-204.</citation>
    <PMID>8962647</PMID>
  </reference>
  <reference>
    <citation>Lessey BA, Castelbaum AJ, Buck CA, Lei Y, Yowell CW, Sun J. Further characterization of endometrial integrins during the menstrual cycle and in pregnancy. Fertil Steril. 1994 Sep;62(3):497-506.</citation>
    <PMID>8062944</PMID>
  </reference>
  <reference>
    <citation>Dehbashi S, Vafaei H, Parsanezhad MD, Alborzi S. Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome. Int J Gynaecol Obstet. 2006 Apr;93(1):44-8. Epub 2006 Mar 10.</citation>
    <PMID>16530767</PMID>
  </reference>
  <reference>
    <citation>Bayar U, Tanriverdi HA, Barut A, Ayoğlu F, Ozcan O, Kaya E. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril. 2006 Apr;85(4):1045-8. Epub 2006 Mar 9.</citation>
    <PMID>16580393</PMID>
  </reference>
  <reference>
    <citation>Lessey BA, Castelbaum AJ, Sawin SW, Sun J. Integrins as markers of uterine receptivity in women with primary unexplained infertility. Fertil Steril. 1995 Mar;63(3):535-42.</citation>
    <PMID>7851583</PMID>
  </reference>
  <reference>
    <citation>Savaris RF, Pedrini JL, Flores R, Fabris G, Zettler CG. Expression of alpha 1 and beta 3 integrins subunits in the endometrium of patients with tubal phimosis or hydrosalpinx. Fertil Steril. 2006 Jan;85(1):188-92.</citation>
    <PMID>16412752</PMID>
  </reference>
  <reference>
    <citation>Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999 Sep 11;319(7211):670-4. Review.</citation>
    <PMID>10480822</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>August 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2016</results_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>clomiphene citrate</keyword>
  <keyword>Raloxifene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between September 2008 and October 2009 at Hospital de Clínicas de Porto Alegre, a tertiary teaching hospital.</recruitment_details>
      <pre_assignment_details>Women were excluded if they had elevated levels of thyroid-stimulating hormone, prolactin, or 17α-hydroxyprogesterone, if they had used oral contraceptives in the previous 2 months, or if they had a history of endometriosis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clomiphene</title>
          <description>Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle</description>
        </group>
        <group group_id="P2">
          <title>Raloxiphene</title>
          <description>Use of 100mg of raloxifene during days 5-9 of the menstrual cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no induction of menses</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age, body mass index (BMI), hormone levels, waist-hip ratio, degree os hirsutism by the Ferriman-Gallwey(FG) score, and fasting glycemia were compared between both groups. The FG represents hair growth in 11 parts in the body, ranging from 0 (no excessive terminal hair growth) to 4 (extensive terminal hair growth) adding up maximum count of 36.</population>
      <group_list>
        <group group_id="B1">
          <title>Raloxifene</title>
          <description>Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
raloxifene: 100mg PO on days 5-9 of the menstrual cycle</description>
        </group>
        <group group_id="B2">
          <title>Clomiphene</title>
          <description>Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
clomiphene citrate: 100mg PO on days 5-9 of the menstrual cycle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.21" spread="5.3"/>
                    <measurement group_id="B2" value="28.7" spread="4.8"/>
                    <measurement group_id="B3" value="28.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Ovulation Detected by Ultrasound</title>
        <description>Ovulation detected by ultrasound was defined as the percentage of a participants with ovulation detected by ultrasound, defined as the dominant follicle and its subsequent collapse. If a dominant follicle was not observed by day 21 after menses, the ovulation induction was considered to be a failure.</description>
        <time_frame>cycle day 14-20</time_frame>
        <population>intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene</title>
            <description>Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle</description>
          </group>
          <group group_id="O2">
            <title>Raloxifene</title>
            <description>Use of 100mg of raloxifene during days 5-9 of the menstrual cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Ovulation Detected by Ultrasound</title>
          <description>Ovulation detected by ultrasound was defined as the percentage of a participants with ovulation detected by ultrasound, defined as the dominant follicle and its subsequent collapse. If a dominant follicle was not observed by day 21 after menses, the ovulation induction was considered to be a failure.</description>
          <population>intention to treat.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="36.1" upper_limit="68.5"/>
                    <measurement group_id="O2" value="40.4" lower_limit="25.6" upper_limit="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no significant difference between two drugs for ovulation induction.A sample size of 40 women per arm was calculated for this superiority trial, considering an alpha and beta error of 0.05 and 0.2, respectively, to find an absolute difference of 30% in the ovulation rate between groups, based on a previous study published by Mitwally and Casper (18) where the ovulation rate with CC was approximately 45%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Progesterone</title>
        <description>The level of serum progesterone that indicated ovulation was considered to be 3 ng/mL or greater, on days 8 to 10 after ovulation.</description>
        <time_frame>8-10 days after ovulation</time_frame>
        <population>Intention to treat.Cases that were lost to follow-up observation, dropped out of the study, failed to collect progesterone on days 22 to 24, and lacked menses after medroxyprogesterone acetate treatment were considered as failures according to the intention-to-treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene</title>
            <description>Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle</description>
          </group>
          <group group_id="O2">
            <title>Raloxiphene</title>
            <description>Use of 100mg of raloxifene during days 5-9 of the menstrual cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Progesterone</title>
          <description>The level of serum progesterone that indicated ovulation was considered to be 3 ng/mL or greater, on days 8 to 10 after ovulation.</description>
          <population>Intention to treat.Cases that were lost to follow-up observation, dropped out of the study, failed to collect progesterone on days 22 to 24, and lacked menses after medroxyprogesterone acetate treatment were considered as failures according to the intention-to-treat analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="13.8" upper_limit="42"/>
                    <measurement group_id="O2" value="40" lower_limit="24.8" upper_limit="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the mean values of progesterone between both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>- 6</ci_lower_limit>
            <ci_upper_limit>34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clomiphene Citrate</title>
          <description>Use of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
clomiphene citrate: 100mg PO on days 5-9 of the menstrual cycle
One woman in the CC group had nausea, headache, and abdominal bloating.</description>
        </group>
        <group group_id="E2">
          <title>Raloxifene</title>
          <description>Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
raloxifene: 100mg PO on days 5-9 of the menstrual cycle
Two cases: one woman had nausea, and the other woman had nausea, headache, and pelvic pain. All mild</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>none in portuguese</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>abdominal bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ricardo Francalacci Savaris</name_or_title>
      <organization>Hospital de Clínicas de Porto Alege</organization>
      <phone>51 33598405</phone>
      <email>rsavaris@hcpa.ufrgs.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

